Enrollment expected to commence Q3 2025. WASHINGTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused ...
US-based pharmaceutical company 60 Degrees Pharmaceuticals has received approval from the investigational review board (IRB) for a Phase II trial of Arakoda (tafenoquine) for treating chronic ...
60 Degrees Pharmaceuticals (SXTP) announced the approval of an Investigational Review Board, IRB, sanctioned Phase II clinical study. The study will evaluate the efficacy and safety of the ARAKODA ...
Enrollment expected to commence Q3 2025. WASHINGTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on ...
60 Degrees Pharmaceuticals, Inc. announced the approval of an Investigational Review Board (IRB) for a Phase II clinical study aimed at evaluating the efficacy and safety of tafenoquine ...
WASHINGTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious ...
WASHINGTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a ...
Babesiosis is a tick-borne illness caused by babesia parasites. Credit: Yuriy K / Shutterstock. US-based pharmaceutical company 60 Degrees Pharmaceuticals has received approval from the ...
Aaaa Aa Aaa Aaa 407.12 +25.05% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback